DIA China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
DIA (Drug Information Association) China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. He has been employed by Roche in China and the U.S., and by other Chinese and international companies, working in R&D, sales and marketing, business development and executive management.
Dong is a full professor at Nanjing University of Technology, and was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington.
This appointment was prompted by the retirement of Jane Cai, PhD, from the role of DIA China regional director. Under her direction, DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Also, participation of attendees and exhibitors in DIA China Annual Meeting participation doubled, as did membership numbers.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.